Casgevy's NICE recommendation creates a £300-600 million a year NHS budget event, while Lyfgenia has no UK regulatory status at all.

The UK has an estimated 15,000-17,000 diagnosed sickle cell disease patients, the largest SCD population in Europe, concentrated in London (6,000+), Birmingham, Manchester, Bristol, and Nottingham. NHS newborn screening has covered SCD since 1999, so virtually every UK patient is diagnosed at birth, with roughly 500 new diagnoses per year. Generic hydroxyurea, established as the NHS disease-modifying standard under NICE clinical guideline CG143 and reinforced by NICE quality standard QS58, remains the dominant therapy for patients with 3 or more vaso-occlusive crises per year and the NHS treatment backbone.

Crizanlizumab (Adakveo) was the only novel VOC-prevention agent to reach the NHS beyond hydroxyurea, but the EMA's CHMP recommended revoking its marketing authorisation in May 2023 after the confirmatory STAND trial failed its primary endpoint. Roughly 300 UK patients who had accessed crizanlizumab through NHS England interim funding reverted to hydroxyurea, leaving a commercial gap in VOC prevention. Gene therapy is now the next market event: Casgevy (exa-cel, Vertex/CRISPR Therapeutics), MHRA-approved in November 2023, holds a positive NICE recommendation under TA1044 for patients aged 12 and over. Lyfgenia (bluebird bio) has no UK regulatory status at all: bluebird bio withdrew from the UK/EU market in 2021 and never submitted it to the MHRA or NICE.

One gene therapy is commissioned; its only US rival was never even filed here.

Five questions this report answers:

Q1 - What outcomes-based contracting let Casgevy secure NHS commissioning at over £1.5 million per patient?

Q2 - Which NHS centres are being designated as SCD gene therapy hubs under TA1044?

Q3 - With crizanlizumab withdrawn, what pharmacological option follows hydroxyurea for VOC prevention?

Q4 - How does NICE clinical guideline CG143 define the hydroxyurea eligibility threshold?

Q5 - Why did bluebird bio never submit Lyfgenia to the MHRA or NICE?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SickleCellDisease #UK #CompetitiveIntelligence #AXLRx #NICE #GeneTherapy

Live report page:  https://axlrx.ai/sickle-cell-disease/uk/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/